A 24-week, Randomized, Double-blind, Multicenter Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of ZD4522 and Atorvastatin in the Treatment of High Risk Hypercholesterolemic Subjects

Study identifier:4522IL/0025

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 24-week, Randomized, Double-blind, Multicenter Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of ZD4522 and Atorvastatin in the Treatment of High Risk Hypercholesterolemic Subjects

Medical condition

hypercholesterolaemia

Phase

N/A

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria